PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis
2 other identifiers
interventional
5
1 country
2
Brief Summary
Inflammation in the vascular wall is important in atherosclerosis and the blockage of the artery. The peripheral benzodiazepine receptor is involved in inflammation and in this protocol we will attempt to take pictures, using PET camera, of inflammation in patients with atherosclerosis and compare those of healthy people.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1
Started Oct 2007
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2007
CompletedFirst Submitted
Initial submission to the registry
October 20, 2007
CompletedFirst Posted
Study publicly available on registry
October 23, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2009
CompletedApril 27, 2012
April 1, 2012
1.8 years
October 20, 2007
April 26, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Binding of [11C]PBR28 at peripheral benzodiazepine receptor
3 years
Secondary Outcomes (1)
PET [F-18]FDG uptake
3 years
Interventions
Eligibility Criteria
You may qualify if:
- Age 18 - 89
- Ability to provide written informed consent
You may not qualify if:
- Severe systemic disease based on history, physical examination or laboratory tests that would prevent participation in the study
- Prior participation in other research protocols in the last year such that radiation exposure would exceed the annual guideline of RSC
- Pregnancy and breast feeding
- Claustrophobia
- Inability to lie flat for a few hours for the PET scans
- Medically unstable
- The blood glucose level is greater than 150 mg/dL after fasting
- Any other condition which in the opinion of the PI would prevent satisfactory participation in and completion of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Suburban Hospital
Bethesda, Maryland, 20814, United States
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Related Publications (4)
Anholt RR, De Souza EB, Oster-Granite ML, Snyder SH. Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther. 1985 May;233(2):517-26.
PMID: 2987488BACKGROUNDAnholt RR, Murphy KM, Mack GE, Snyder SH. Peripheral-type benzodiazepine receptors in the central nervous system: localization to olfactory nerves. J Neurosci. 1984 Feb;4(2):593-603. doi: 10.1523/JNEUROSCI.04-02-00593.1984.
PMID: 6321699BACKGROUNDBanati RB. Visualising microglial activation in vivo. Glia. 2002 Nov;40(2):206-217. doi: 10.1002/glia.10144.
PMID: 12379908BACKGROUNDSchollhammer R, Lepreux S, Barthe N, Vimont D, Rullier A, Sibon I, Berard X, Zhang A, Kimura Y, Fujita M, Innis RB, Zanotti-Fregonara P, Morgat C. In vitro and pilot in vivo imaging of 18 kDa translocator protein (TSPO) in inflammatory vascular disease. EJNMMI Res. 2021 May 5;11(1):45. doi: 10.1186/s13550-021-00786-7.
PMID: 33950298DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- NIH
Study Record Dates
First Submitted
October 20, 2007
First Posted
October 23, 2007
Study Start
October 1, 2007
Primary Completion
August 1, 2009
Study Completion
August 1, 2009
Last Updated
April 27, 2012
Record last verified: 2012-04